These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 35328342)

  • 1. The Rationale for the Dual-Targeting Therapy for RSK2 and AKT in Multiple Myeloma.
    Isa R; Horinaka M; Tsukamoto T; Mizuhara K; Fujibayashi Y; Taminishi-Katsuragawa Y; Okamoto H; Yasuda S; Kawaji-Kanayama Y; Matsumura-Kimoto Y; Mizutani S; Shimura Y; Taniwaki M; Sakai T; Kuroda J
    Int J Mol Sci; 2022 Mar; 23(6):. PubMed ID: 35328342
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serine-227 in the N-terminal kinase domain of RSK2 is a potential therapeutic target for mantle cell lymphoma.
    Matsumura-Kimoto Y; Tsukamoto T; Shimura Y; Chinen Y; Tanba K; Kuwahara-Ota S; Fujibayashi Y; Nishiyama D; Isa R; Yamaguchi J; Kawaji-Kanayama Y; Kobayashi T; Horiike S; Taniwaki M; Kuroda J
    Cancer Med; 2020 Jul; 9(14):5185-5199. PubMed ID: 32420699
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RSK2(Ser227) at N-terminal kinase domain is a potential therapeutic target for multiple myeloma.
    Shimura Y; Kuroda J; Ri M; Nagoshi H; Yamamoto-Sugitani M; Kobayashi T; Kiyota M; Nakayama R; Mizutani S; Chinen Y; Sakamoto N; Matsumoto Y; Horiike S; Shiotsu Y; Iida S; Taniwaki M
    Mol Cancer Ther; 2012 Dec; 11(12):2600-9. PubMed ID: 23012246
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epigenetic repression of miR-375 is the dominant mechanism for constitutive activation of the PDPK1/RPS6KA3 signalling axis in multiple myeloma.
    Tatekawa S; Chinen Y; Ri M; Narita T; Shimura Y; Matsumura-Kimoto Y; Tsukamoto T; Kobayashi T; Kawata E; Uoshima N; Taki T; Taniwaki M; Handa H; Iida S; Kuroda J
    Br J Haematol; 2017 Aug; 178(4):534-546. PubMed ID: 28439875
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Triple targeting of RSK, AKT, and S6K as pivotal downstream effectors of PDPK1 by TAS0612 in B-cell lymphomas.
    Katsuragawa-Taminishi Y; Mizutani S; Kawaji-Kanayama Y; Onishi A; Okamoto H; Isa R; Mizuhara K; Muramatsu A; Fujino T; Tsukamoto T; Shimura Y; Taniwaki M; Miyagawa-Hayashino A; Konishi E; Kuroda J
    Cancer Sci; 2023 Dec; 114(12):4691-4705. PubMed ID: 37840379
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phosphoinositide protein kinase PDPK1 is a crucial cell signaling mediator in multiple myeloma.
    Chinen Y; Kuroda J; Shimura Y; Nagoshi H; Kiyota M; Yamamoto-Sugitani M; Mizutani S; Sakamoto N; Ri M; Kawata E; Kobayashi T; Matsumoto Y; Horiike S; Iida S; Taniwaki M
    Cancer Res; 2014 Dec; 74(24):7418-29. PubMed ID: 25269480
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phosphoinositide-dependent protein kinase 1 is a potential novel therapeutic target in mantle cell lymphoma.
    Maegawa S; Chinen Y; Shimura Y; Tanba K; Takimoto T; Mizuno Y; Matsumura-Kimoto Y; Kuwahara-Ota S; Tsukamoto T; Kobayashi T; Horiike S; Taniwaki M; Kuroda J
    Exp Hematol; 2018 Mar; 59():72-81.e2. PubMed ID: 29287939
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel wiring of the AKT-RSK2 signaling pathway plays an essential role in cancer cell proliferation via a G
    Choi JS; Cho YY
    Biochem Biophys Res Commun; 2023 Jan; 642():66-74. PubMed ID: 36566564
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RNA interference screening identifies lenalidomide sensitizers in multiple myeloma, including RSK2.
    Zhu YX; Yin H; Bruins LA; Shi CX; Jedlowski P; Aziz M; Sereduk C; Kortuem KM; Schmidt JE; Champion M; Braggio E; Keith Stewart A
    Blood; 2015 Jan; 125(3):483-91. PubMed ID: 25395420
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Downregulation of RSK2 influences the biological activities of human osteosarcoma cells through inactivating AKT/mTOR signaling pathways.
    Qiu Q; Jiang J; Lin L; Cheng S; Xin D; Jiang W; Shen J; Hu Z
    Int J Oncol; 2016 Jun; 48(6):2508-20. PubMed ID: 27082640
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced sensitivity of multiple myeloma cells containing PTEN mutations to CCI-779.
    Shi Y; Gera J; Hu L; Hsu JH; Bookstein R; Li W; Lichtenstein A
    Cancer Res; 2002 Sep; 62(17):5027-34. PubMed ID: 12208757
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FGFR3 activates RSK2 to mediate hematopoietic transformation through tyrosine phosphorylation of RSK2 and activation of the MEK/ERK pathway.
    Kang S; Dong S; Gu TL; Guo A; Cohen MS; Lonial S; Khoury HJ; Fabbro D; Gilliland DG; Bergsagel PL; Taunton J; Polakiewicz RD; Chen J
    Cancer Cell; 2007 Sep; 12(3):201-14. PubMed ID: 17785202
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serotonin-induced growth of pulmonary artery smooth muscle requires activation of phosphatidylinositol 3-kinase/serine-threonine protein kinase B/mammalian target of rapamycin/p70 ribosomal S6 kinase 1.
    Liu Y; Fanburg BL
    Am J Respir Cell Mol Biol; 2006 Feb; 34(2):182-91. PubMed ID: 16195541
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of the phosphatidylinositol 3-kinase/Akt and mTOR/P70S6-kinase pathways in the proliferation and apoptosis in multiple myeloma.
    Pene F; Claessens YE; Muller O; Viguié F; Mayeux P; Dreyfus F; Lacombe C; Bouscary D
    Oncogene; 2002 Sep; 21(43):6587-97. PubMed ID: 12242656
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin-like growth factor receptor/insulin receptor substrate-1/phosphatidylinositol 3-kinase cascade.
    Shi Y; Yan H; Frost P; Gera J; Lichtenstein A
    Mol Cancer Ther; 2005 Oct; 4(10):1533-40. PubMed ID: 16227402
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Loss of serum and glucocorticoid-regulated kinase 3 (SGK3) does not affect proliferation and survival of multiple myeloma cell lines.
    Hausmann S; Brandt E; Köchel C; Einsele H; Bargou RC; Seggewiss-Bernhardt R; Stühmer T
    PLoS One; 2015; 10(4):e0122689. PubMed ID: 25837824
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phosphoserine/threonine-binding pocket in AGC kinases and PDK1 mediates activation by hydrophobic motif phosphorylation.
    Frödin M; Antal TL; Dümmler BA; Jensen CJ; Deak M; Gammeltoft S; Biondi RM
    EMBO J; 2002 Oct; 21(20):5396-407. PubMed ID: 12374740
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MK2206 enhances the cytocidal effects of bufalin in multiple myeloma by inhibiting the AKT/mTOR pathway.
    Xiang RF; Wang Y; Zhang N; Xu WB; Cao Y; Tong J; Li JM; Wu YL; Yan H
    Cell Death Dis; 2017 May; 8(5):e2776. PubMed ID: 28492559
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Knockdown of c-Met enhances sensitivity to bortezomib in human multiple myeloma U266 cells via inhibiting Akt/mTOR activity.
    Que W; Chen J; Chuang M; Jiang D
    APMIS; 2012 Mar; 120(3):195-203. PubMed ID: 22339676
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-myeloma activity of Akt inhibition is linked to the activation status of PI3K/Akt and MEK/ERK pathway.
    Ramakrishnan V; Kimlinger T; Haug J; Painuly U; Wellik L; Halling T; Rajkumar SV; Kumar S
    PLoS One; 2012; 7(11):e50005. PubMed ID: 23185517
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.